1. Home
  2. IFRX vs CAAS Comparison

IFRX vs CAAS Comparison

Compare IFRX & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • CAAS
  • Stock Information
  • Founded
  • IFRX 2007
  • CAAS N/A
  • Country
  • IFRX Germany
  • CAAS China
  • Employees
  • IFRX N/A
  • CAAS N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • CAAS Auto Parts:O.E.M.
  • Sector
  • IFRX Health Care
  • CAAS Consumer Discretionary
  • Exchange
  • IFRX Nasdaq
  • CAAS Nasdaq
  • Market Cap
  • IFRX 117.8M
  • CAAS 137.0M
  • IPO Year
  • IFRX 2017
  • CAAS N/A
  • Fundamental
  • Price
  • IFRX $1.05
  • CAAS $4.17
  • Analyst Decision
  • IFRX Strong Buy
  • CAAS
  • Analyst Count
  • IFRX 2
  • CAAS 0
  • Target Price
  • IFRX $9.00
  • CAAS N/A
  • AVG Volume (30 Days)
  • IFRX 356.5K
  • CAAS 59.0K
  • Earning Date
  • IFRX 03-20-2025
  • CAAS 03-28-2025
  • Dividend Yield
  • IFRX N/A
  • CAAS N/A
  • EPS Growth
  • IFRX N/A
  • CAAS N/A
  • EPS
  • IFRX N/A
  • CAAS 0.99
  • Revenue
  • IFRX $171,642.00
  • CAAS $650,935,000.00
  • Revenue This Year
  • IFRX $381.73
  • CAAS $4.97
  • Revenue Next Year
  • IFRX $2,277.23
  • CAAS N/A
  • P/E Ratio
  • IFRX N/A
  • CAAS $4.46
  • Revenue Growth
  • IFRX 162.79
  • CAAS 12.94
  • 52 Week Low
  • IFRX $1.01
  • CAAS $3.34
  • 52 Week High
  • IFRX $2.82
  • CAAS $5.37
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 31.57
  • CAAS 41.76
  • Support Level
  • IFRX $1.16
  • CAAS $4.17
  • Resistance Level
  • IFRX $1.30
  • CAAS $5.37
  • Average True Range (ATR)
  • IFRX 0.12
  • CAAS 0.27
  • MACD
  • IFRX 0.02
  • CAAS -0.03
  • Stochastic Oscillator
  • IFRX 9.76
  • CAAS 5.44

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, more than 310 models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: